Never miss a great news story!
Get instant notifications from Economic Times
AllowNot now


You can switch off notifications anytime using browser settings.

Portfolio

Loading...
Select Portfolio and Asset Combination for Display on Market Band
Select Portfolio
Select Asset Class
Show More
Download ET MARKETS APP

Get ET Markets in your own language

DOWNLOAD THE APP NOW

+91

CHOOSE LANGUAGE

ENG

  • ENG - English
  • HIN - हिन्दी
  • GUJ - ગુજરાતી
  • MAR - मराठी
  • BEN - বাংলা
  • KAN - ಕನ್ನಡ
  • ORI - ଓଡିଆ
  • TEL - తెలుగు
  • TAM - தமிழ்
Drag according to your convenience
ET NOW RADIO
ET NOW
TIMES NOW

Metropolis Healthcare gains 9% on market debut

The Rs 1,204 crore IPO, which was sold between April 3 to April 5, was subscribed 5.83 times.

ETMarkets.com|
Updated: Apr 15, 2019, 04.30 PM IST
0Comments
Getty Images
Rise-gain---Getty
At the issue price, the stock was valued at of 39 times FY19 annualised earnings against Dr Lal Pathlabs’ 43 times.
NEW DELHI: Metropolis Healthcare on Monday made a decent market debut, as the scrip got listed at Rs 960 on BSE, a 9.09 per cent premium over issue price of Rs 880 per share.

The scrip closed at Rs 959.55, up 9.04 per cent with respect to its issue price.

The Rs 1,204 crore IPO, which was sold between April 3 to April 5, was subscribed 5.83 times.

At the issue price, the stock was valued at of 39 times FY19 annualised earnings against Dr Lal Pathlabs’ 43 times.

Metropolis’ laboratory network consists of 115 clinical laboratories, comprising a global reference laboratory located in Mumbai, 14 regional reference laboratories 56 satellite laboratories and 44 express laboratories.

The diagnostic company, which offers approximately 3,487 clinical laboratory tests and 530 profiles, has presence across 19 states and a leadership position in West and South India through its network of 83 clinical laboratories, 1,473 patient touch points and 396 ARCs (assisted referral centres) in the regions.

The revenue from operations rose at a CAGR of 16.3 per cent to Rs 643.6 crore from FY16 to FY18, while profits climbed at a CAGR of 15.7 per cent to Rs 109.7 crore. The company is debt free.

In nine months to December 31, 2018, the diagnostic company conducted 12.3 million tests on 6.6 million patients compared with 16 million tests on 7.7 million patients in in the entire FY18.
0Comments

Also Read

MyHealthcare raises $3 million in Series A

Healthcare app mfine in talks to raise $17 million

Healthcare Startups have finger on the pulse

Metropolis Healthcare IPO subscribed 47% on Day 2

Comments
Add Your Comments
Commenting feature is disabled in your country/region.
Download The Economic Times Business News App for the Latest News in Business, Share Market & More.

Other usefull Links


Follow us on


Download et app


Copyright © 2019 Bennett, Coleman & Co. Ltd. All rights reserved. For reprint rights: Times Syndication Service